inflammatory bowel disease steven n. carter, md colon and rectal surgery assistant professor...
TRANSCRIPT
![Page 1: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/1.jpg)
Inflammatory Bowel Disease
Steven N. Carter, MDColon and Rectal Surgery
Assistant ProfessorUniversity of Oklahoma
![Page 2: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/2.jpg)
Crohn’s and Colitis Clinic: 405-271-8478Clinic appointment: 405-271-8478
IBD Nurse Practioner: 405-271-5428 Ext. 53424IBD Center Office: 405-271-5428
Office fax: 405-271-5803GI Endoscopy lab: 405-271-8737
OUMC operator: 405-271-5656Colon and Rectal Surgery Clinic 405-271-1400
![Page 3: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/3.jpg)
Objectives
• 1. Discuss the diagnosis and evaluation of suspected inflammatory bowel disease.
• 2. Be able to differentiate Crohn's disease from Ulcerative Colitis.
• 3. Discuss treatment and surveillance of inflammatory bowel disease.
• No Disclosures
![Page 4: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/4.jpg)
Inflammatory Bowel Disease
• Epidemiology• Classification• Evaluation• Treatment• Surveillance• Simply Case Presentations
![Page 5: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/5.jpg)
![Page 6: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/6.jpg)
Inflammatory Bowel Disease• 1932 – Crohn, Ginzburg, and Oppenheimer
described 13 cases if regional ileitis• 1959 & 1960 – Brooke and Lockart-Mummery
described the segmental nature of Crohn’s Colitis
• 1959-Truelove and Witts high dose cortisone for CD
• 1978- Parks and Nicholls describe ILAA 1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. AMA Am J Dis Child, 1932; 99: 1323-9.
2. 2. Brooke BN. Granulomatous disease of the intestine. Lancet 1959; 2 (7106):745-9.3. Lockhart-Mummert HE, Morson BC. Crohn’s disese (regional enteritis)of the large intestine and its distinction from UC. Gut. 1960; 1:87-105.
4. Truelove SC, Witts LJ, Bourne WA, et al. Cortisone and cortitropin in UC. Br Journal of Medicine. 1959; 1(5119): 387-94.5. Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for UC. British Journal of Medicine. 1978; 2:85-88.
![Page 7: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/7.jpg)
Epidemiology
• Prevalence varies greatly throughout the world– Symptoms often wax and wane
• Incidence has been increasing over the past 20-30 years– Crohn’s 5/100k annually– UC .5-24.5/100k annually– Suggests an environmental component
• Occurs in the 2nd-3rd decade of life1. Loftus Jr. EV, Schoenfeld P., Sandborn, WJ. The epidemology and natural history of Crohn’s disease in population based patient
cohorts from North America: a systemic review. Aliment Pharmacol Ther. 2002; 16: 51-60.2. CDC
![Page 8: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/8.jpg)
Epidemiology
• Interplay between environment and genes• The relative risk for concordance of CD in a
monozygotic twin pair is approximately 800-fold greater than the general population– Less so for UC
• Some examples of early IBD related to genetic defects in T-Cell regulation, cytokines, etc.
Kaser A, et. Al. Genes and Environment: How Will Our Concepts on the Pathophysiology of IBD Develop in the Future? Genes and Environment: How Will Our Concepts on the Pathophysiology of IBD Develop in the Future? Dig Dis. 2010 October; 28(3): 395–405.
![Page 9: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/9.jpg)
Epidemiology
Kaser A, et. Al. Genes and Environment: How Will Our Concepts on the Pathophysiology of IBD Develop in the Future? Genes and Environment: How Will Our Concepts on the Pathophysiology of IBD Develop in the Future? Dig Dis. 2010 October; 28(3): 395–405.
![Page 10: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/10.jpg)
Hygiene Hypothesis
• Helminthes have colonized humans for thousands of years.
• Immunological influence on host cells– Prevent excessive immune response
• Aggressive hygienic practices in the West may negatively affects immune system development
• Therapeutic implications
Weinstock JV and Elliot DE. Helminths and the IBD Hygiene Hypothesi. Inflammatory Bowel Disease. 2009 January; 15 (1) 128-133.
![Page 11: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/11.jpg)
Epidemilogy
• Whites & Blacks >> Hispanics and Asians• Northern Climates• Urban>Rural• Sugar Consumption (Crohn’s)• EtOH (decreases UC incidence)• Higher socioeconomic status• OCP’s• Cigarettes
– Decrease in UC– Increase in CD
• Appendectomy – decreases incidence in Crohn’sASCRS Textbook
![Page 12: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/12.jpg)
Classification and DiagnosisCrohn’s Disease vs Ulcerative Colitis
![Page 13: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/13.jpg)
Crohn’s Disease• 75% complain of Abdominal pain and Diarrhea• 40-60% complain of Wt Loss, Fever, and bleeding• Many different classification systems have been
proposed– Vienna classification is based on behavior
• Stricture vs Fistula• Most important predictor of future disease is past behavior
– Mostly academic• Majority of patients have years of quiescence (60-70%)– 10-20% have chronic unrelenting disease
ASCRS Textbook
![Page 14: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/14.jpg)
Munkholm et al
• Regional Cohort Study– Copenhagen – 373 patients– 1962-1987
• Examined the long term disease course of Crohn’s disease– Remission Predictive Factors– Relapse Predictive Factors
Munkholm P, Langholz M, et a. Disease Activity Courses in a Regional Cohort of Crohn’s Disease patients. Scandanavian Journal of Gastro. 1995 Jul;30(7):699-706.
![Page 15: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/15.jpg)
Probability of only having one attack
~22% at 5 years
Munkholm P, Langholz M, et a. Disease Activity Courses in a Regional Cohort of Crohn’s Disease patients. Scandanavian Journal of Gastro. 1995 Jul;30(7):699-706.
![Page 16: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/16.jpg)
• One year probability of having active disease vs remission
• Patients with Active Disease the Year before
Active Disease
Remission
Munkholm P, Langholz M, et a. Disease Activity Courses in a Regional Cohort of Crohn’s Disease patients. Scandanavian Journal of Gastro. 1995 Jul;30(7):699-706.
Active Disease the Year Prior
![Page 17: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/17.jpg)
Active Disease
Remission
• One year probability of having active disease vs remission
• Patients in Remission the year beforeMunkholm P, Langholz M, et a. Disease Activity Courses in a Regional Cohort of Crohn’s Disease patients. Scandanavian
Journal of Gastro. 1995 Jul;30(7):699-706.
Remission the Year Prior
![Page 18: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/18.jpg)
• Active Disease imparts a 70-80% probability of maintaining a similar state the following year
• Remission imparts a 80% probability of remission the following year
• Regardless of year after diagnosis
Munkholm P, Langholz M, et a. Disease Activity Courses in a Regional Cohort of Crohn’s Disease patients. Scandanavian Journal of Gastro. 1995 Jul;30(7):699-706.
![Page 19: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/19.jpg)
Crohn’s DiseaseCrohn’s Disease-40% of patients-Abdominal pain-Also associated with perianal disease
Colonic Disease-30% of patients-Diarrhea and bleeding
![Page 20: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/20.jpg)
Stricture
Fistula
Acute
Chronic
Crohn’s flare / exacerbation
![Page 21: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/21.jpg)
Ulcerative Colitis
• Extent of disease is related to location– Always starts at Rectum and extends proximally– No skip lesions
• Bloody and Mucus diarhea• Rectal disease
– Diarrhea– Hematochezia– Tenesmus– Incontinence
• Proximal Disease– Wt loss– Abdominal Pain
![Page 22: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/22.jpg)
GI SymptomsSigns and Symptoms
• Crohn’s– Mouth to Anus– Discontinuous– Transmural inflammation– Most common
complaint: pain + diarrhea
• U.C.– Rectum and moves
proximally – Continuous– Mucosal Disease
• Severe disease can be transmural
– Classical Bloody Diarrhea
Indeterminate Colitis
![Page 23: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/23.jpg)
Extraintestinal Manifestations
• Musculoskeletal – Osteoporosis/osteopenia– Arthritis• Ankylosing Spondylitis (5%)
• Pyoderma Gangrenosum• Primary Sclerosing Cholangitis – UC• Ophthalmological • Coagulopathy
http://en.wikipedia.org/wiki/File:Crohnie_Pyoderma_gangrenosum.jpgASCRS textbook
![Page 24: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/24.jpg)
Evaluation
• Difficult to make diagnosis• Rule out infectious sources– C. Diff– Stool Studies
• Diagnosis is dependent – Clinical suspicion– Radiological evaluation – Pathology
![Page 25: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/25.jpg)
Radiology
• Abdominal X-Ray– Signs of obstruction– Loss of haustra markings
• Contrast Studies (Small Bowel Follow Through)– Crohn’s SB Strictures/Fistulas– Superior to CT’s for many fistulas
• Computed Tomography – Evaluate thickness of the bowel– r/o other etiologies of abdominal pain
• MRI
![Page 26: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/26.jpg)
Evaluation
• Colonoscopy is the study of choice for patients suspected of having UC or colonic involvement of Crohn’s– Allows for pathology– Monitor response to treatment– Cancer surveillance
• Office procedures include rigid proctoscopy and flexible sigmoidoscopy
![Page 27: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/27.jpg)
Serum Tests
• Acute phase reactants– ESR and C-Reactive Protein– Active disease vs stricture
• Nutritional parameters• Immune regulatory pathway markers– Aid in differentiating Crohn’s vs UC
• Any patient with diarrhea or suspected of having a flare should have common causes ruled out – C. Diff– Stool cultures
![Page 28: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/28.jpg)
Standard Workup in Acute Settings
• Stabilize the patient• Basic labs, CRP and ESR• Infectious workup– Empiric antibiotics?
• Abdominal Series• Colonoscopy vs CT of Abd/Pelvis– Bloody Diarrhea – Colonoscopy– Abdominal Pain -- CT
![Page 29: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/29.jpg)
TreatmentAs far as I’m concerned, if something is so complicated that you can’t explain it in 10 seconds, then it’s probably not worth knowing anyway.
![Page 30: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/30.jpg)
Treatment
• Crohn’s vs UC– Location of Crohn’s– Behavior of Crohn’s
• Acute vs Chronic Pathology
![Page 31: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/31.jpg)
Stricture
Fistula
Acute/Medical management
Chronic/Surgery
Crohn’s Disease
![Page 32: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/32.jpg)
Crohn’s DiseaseMedical Management
• Mild to Moderate Disease– Sulfasalazines– 5-Aminosalicylates– Antibiotics• Ciprofloxacin has been shown to be as effective as 5-
ASA compounds in mild-moderate disease• Metronidazole
– Budesonide• Topical Steroid
![Page 33: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/33.jpg)
Medical Management
• Mild to Severe – Steroids– Immunomodulators• 6-mercaptopurine• Azathioprine• Delayed benefit, durable results
– Methotrexate– Biologic Therapy
![Page 34: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/34.jpg)
Top – Down Approach
• SONIC Trial 2010– 508 randomized– Overall looked at
280 patients at 26 weeks
– Extended to 50 weeks with similar results.
![Page 35: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/35.jpg)
Top Down Approach• CHARM Study
– 854 Patients– Placebo vs adalimunab– Adalimunab has a 50%
reduction in all hospitalizations compared to placebo
• 33% will eventually fail to respond to biological therapy– Antibody formation may
reduce effectiveness over time• Combination therapy may
alleviate this.
Hanauer SB, Feagan BG, Lichtenstein GR. et al. Maintance Infliximab for CD: the ACCENT I randomized trial. Lancet. 2002; 359(9317):1541-9.
Week 26 Week 560
5
10
15
20
25
30
35
40
Placebo Adalimumab 40 mg EOW
Weekly
Patie
nts
%
![Page 36: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/36.jpg)
Top Down Approach
![Page 37: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/37.jpg)
Surgery and Crohn’s Disease
• Not Curable• Conservative Resection• Area of previous anastomosis is most likely site of
recurrence• Indications– Obstruction– Fistula– Hemorrhage– Colitis– Neoplasia– Failed medical management
![Page 38: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/38.jpg)
Ulcerative Colitis
• Colonoscopy to evaluate extent of disease• Mild to Moderate and Distal to the splenic
flexure– Topical steroids, 5-ASA– Oral – 5-ASA
• Mild to Moderate and proximal to the splenic flexure – 5-ASA– Steroids
![Page 39: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/39.jpg)
Ulcerative Colitis Treatment
• Goal is mucosal healing• Severe colitis– Intravenous Steroids– Azathioprine– 6-mercaptopurine– Cyclosporine– Tacrolimus– Infliximab (Remicade)• Decreases rate of colectomy at 3 months and 1 year
![Page 40: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/40.jpg)
Ulcerative Colitis and Surgery
• 20-30% of patients will require surgery• Emergent/Urgent Indications– Hemorrhage– Toxic Megacolon– Perforation– Serve Colitis unresponsive to medial management
• Elective Indications– Cancer/Dysplasia– Adverse events/symptoms from medical therapy– Medical Failure
![Page 41: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/41.jpg)
Ulcerative colitis
• Emergent Surgery– Total Colectomy with end ileostomy– Reversal at a later date
• Elective– Total Colectomy with end ileostomy– Total Colectomy with ileorectal anastomosis– Total Proctocolectomy with Ileostomy– Total Proctocolectomy with Ileo-anal Anastomosis• Procedure of choice
– Continent ileostomies
![Page 42: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/42.jpg)
Ulcerative Colitis – J-Pouch
• Removal of all colon and rectum
• Patients can expect to have 6 BM’s per day– Control with Immodium or
Lomotil– Minor Incontinence
• Stricures 5-35%• Pouchitis
![Page 43: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/43.jpg)
J-Pouch
• Over 95% are happy with their pouches and would not go back to a ileostomy
• Perianal Hygiene– Hairdryer– Moisture Barrier– Pad
• Failures – Crohn’s– Pelvic Sepsis– Poor Function ASCRS Textbook
![Page 44: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/44.jpg)
Surveillance
• Crohn’s Colitis and Ulcerative Colitis– Random Biopsies to r/o Dysplasia every 1-2 years– Age to begin Screening• 7-8 years after onset of pan colitis• 12-15 years after the onset of left sided colitis
• Ulcerative Colitis– 10% risk of Cancer after 20y of disease– All UC patients have a 4% prevalence of cancer
ASCRS TextbookASCRS Practice Parameters
![Page 45: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/45.jpg)
Crohn’s disease and Surveillance
• Relative Risk of Developing Cancer compared to general population– Small Bowel – 28.4– Colorectal – 2.4– Extra-intestinal Cancer -1.27– Lymphoma – 1.42
![Page 46: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/46.jpg)
Diarrhea in the IBD patient
• Common things are common• C. Diff• Stool studies• Colonoscopy vs Flexible sigmoidoscopy• Treatment– Cipro/Flagyl– Probiotics• Xifanin
![Page 47: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/47.jpg)
Small Bowel Obstruction in Crohn’s
• Etiology• CRP/ESR along with basic labs• Patience• If active flare -7-10 course of steroids– Unlikely to resolve after this.
![Page 48: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/48.jpg)
Conclusion
• 40yo/female with LLQ crampy abdominal pain and watery diarrhea– Colonoscopy– Imaging– Stool Studies– Treatment• Probiotics• Antibiotics• 5-ASA• Budesonide• Biological Therapy
![Page 49: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/49.jpg)
Conclusion
• 32yo/male complains of bloody diarrhea– Toxic?– Endoscopy– Stool Studies– Treatment• 5-ASA• Probiotics• Steroids?• Remicade
![Page 50: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/50.jpg)
Conclusion
• Inflammatory Bowel Disease requires a high degree of suspicion to make the diagnosis
• Appropriate imaging or endoscopy can greatly aid in the diagnosis
• Treatment should be tailored to the individual patient
• Cancer screening must be addressed in all IBD patients
![Page 51: Inflammatory Bowel Disease Steven N. Carter, MD Colon and Rectal Surgery Assistant Professor University of Oklahoma](https://reader035.vdocuments.us/reader035/viewer/2022062718/56649eac5503460f94bb2fd5/html5/thumbnails/51.jpg)
Crohn’s and Colitis Clinic: 405-271-8478Clinic appointment: 405-271-8478
IBD Nurse Practioner: 405-271-5428 Ext. 53424IBD Center Office: 405-271-5428
Office fax: 405-271-5803GI Endoscopy lab: 405-271-8737
OUMC operator: 405-271-5656Colon and Rectal Surgery Clinic 405-271-1400